...
search icon
rnaz-img

Transcode Therapeutics Inc Share Price

RNAZ
NAQ
$9.2
+$0.54
(6.24%)
1D
Industry: Biotechnology Sector: Health Care

Transcode Therapeutics Inc Analyst Forecast

Transcode Therapeutics Inc Share Price Chart

Transcode Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.94M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
34.06K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.56
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.08 L
$303.52 H
$9.2

About Transcode Therapeutics Inc, Common Stock

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Transcode Therapeutics Inc Stock Returns

Time FrameRNAZSectorS&P500
1-Week Return-8.46%0.72%-1.31%
1-Month Return5.26%1.27%0.78%
3-Month Return1.88%3.13%3.46%
6-Month Return-12.38%15.81%6.19%
1-Year Return-96.93%8.89%11.68%
3-Year Return-100%20.79%71.21%
5-Year Return-100%35.89%74.81%

Transcode Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-42.47K98.61K516.75K534.86K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":7.94,"profit":true},{"date":"2022-12-31","value":18.44,"profit":true},{"date":"2023-12-31","value":96.61,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit-(42.47K)(98.61K)(516.75K)(534.86K)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-4247000,"profit":false},{"date":"2022-12-31","value":-9860600,"profit":false},{"date":"2023-12-31","value":-51674600,"profit":false},{"date":"2024-12-31","value":-53485700,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses726.60K6.11M18.57M18.90M15.13M[{"date":"2020-12-31","value":3.84,"profit":true},{"date":"2021-12-31","value":32.32,"profit":true},{"date":"2022-12-31","value":98.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":80.02,"profit":true}]
Operating Income(726.60K)(6.15M)(18.67M)(19.42M)(15.66M)[{"date":"2020-12-31","value":-72660400,"profit":false},{"date":"2021-12-31","value":-615113500,"profit":false},{"date":"2022-12-31","value":-1866581400,"profit":false},{"date":"2023-12-31","value":-1941851600,"profit":false},{"date":"2024-12-31","value":-1566069700,"profit":false}]
Total Non-Operating Income/Expense(2.01M)(786.67K)1.12M887.21K(1.72M)[{"date":"2020-12-31","value":-179.42,"profit":false},{"date":"2021-12-31","value":-70.16,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":79.13,"profit":true},{"date":"2024-12-31","value":-153.16,"profit":false}]
Pre-Tax Income(2.34M)(6.84M)(17.56M)(18.55M)(16.75M)[{"date":"2020-12-31","value":-234389300,"profit":false},{"date":"2021-12-31","value":-684339900,"profit":false},{"date":"2022-12-31","value":-1756496800,"profit":false},{"date":"2023-12-31","value":-1854609500,"profit":false},{"date":"2024-12-31","value":-1675497100,"profit":false}]
Income Taxes394.44K95.07K17.56M4.00(16.79B)[{"date":"2020-12-31","value":2.25,"profit":true},{"date":"2021-12-31","value":0.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-95562.78,"profit":false}]
Income After Taxes(2.74M)(6.94M)(35.13M)(18.55M)16.77B[{"date":"2020-12-31","value":-0.02,"profit":false},{"date":"2021-12-31","value":-0.04,"profit":false},{"date":"2022-12-31","value":-0.21,"profit":false},{"date":"2023-12-31","value":-0.11,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(2.34M)(6.84M)(17.56M)(19.59M)(16.75M)[{"date":"2020-12-31","value":-234389300,"profit":false},{"date":"2021-12-31","value":-684339900,"profit":false},{"date":"2022-12-31","value":-1756496800,"profit":false},{"date":"2023-12-31","value":-1959260400,"profit":false},{"date":"2024-12-31","value":-1675497100,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(2.34M)(6.84M)(17.56M)(18.55M)(16.75M)[{"date":"2020-12-31","value":-234389300,"profit":false},{"date":"2021-12-31","value":-684339900,"profit":false},{"date":"2022-12-31","value":-1756496800,"profit":false},{"date":"2023-12-31","value":-1854609500,"profit":false},{"date":"2024-12-31","value":-1675497100,"profit":false}]
EPS (Diluted)-0.08(1.31)(632.68)(28.81K)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1637.5,"profit":false},{"date":"2023-12-31","value":-790850.75,"profit":false},{"date":"2024-12-31","value":-36009055.87,"profit":false}]

Transcode Therapeutics Inc Ratios

Transcode Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

RNAZ
Cash Ratio 0.96
Current Ratio 1.60

Transcode Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RNAZ
ROA (LTM) -232.54%
ROE (LTM) -1763.01%

Transcode Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RNAZ
Debt Ratio Lower is generally better. Negative is bad. 0.73
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.27

Transcode Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RNAZ
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 5.94
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Transcode Therapeutics Inc share price today?

Transcode Therapeutics Inc (RNAZ) share price today is $9.2

Can Indians buy Transcode Therapeutics Inc shares?

Yes, Indians can buy shares of Transcode Therapeutics Inc (RNAZ) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNAZ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Transcode Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Transcode Therapeutics Inc (RNAZ) via the Vested app. You can start investing in Transcode Therapeutics Inc (RNAZ) with a minimum investment of $1.

How to invest in Transcode Therapeutics Inc shares from India?

You can invest in shares of Transcode Therapeutics Inc (RNAZ) via Vested in three simple steps:

  • Click on Sign Up or Invest in RNAZ stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Transcode Therapeutics Inc shares
What is Transcode Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Transcode Therapeutics Inc (RNAZ) is $303.52. The 52-week low price of Transcode Therapeutics Inc (RNAZ) is $6.08.

What is Transcode Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Transcode Therapeutics Inc (RNAZ) is

What is Transcode Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Transcode Therapeutics Inc (RNAZ) is 5.94

What is Transcode Therapeutics Inc dividend yield?

The dividend yield of Transcode Therapeutics Inc (RNAZ) is 0.00%

What is the Market Cap of Transcode Therapeutics Inc?

The market capitalization of Transcode Therapeutics Inc (RNAZ) is $7.94M

What is Transcode Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Transcode Therapeutics Inc is RNAZ

How Can Investors Use Transcode Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Transcode Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Transcode Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Transcode Therapeutics Inc shares for Indian investors?

When investing in Transcode Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Transcode Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Transcode Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Transcode Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Transcode Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top